Diabetes is a primary risk factor for atherosclerotic cardiovascular disease. Find out how well you know the guideline recommendations for reducing that risk with the first of 4 quizzes.
Veronica Hackethal MD
Advertisement
Articles by Veronica Hackethal MD
SGLT2 inhibitors and GLP-1 receptor agonists are changing the type 2 diabetes treatment paradigm. We summarize the most recent data here and offer guidance on patient benefits.
Migraine-especially with aura-is a CV risk factor, which makes treatment with ergots or triptans potentially problematic. The best approach?
Advertisement
Latest Updated Articles
SGLT2 Inhibitors & GLP-1 Receptor Agonists: Differences, Similarities, Patient SelectionPublished: July 2nd 2020 | Updated:
Managing Diabetes to Prevent Cardiovascular Disease: A Guideline QuizPublished: October 9th 2020 | Updated:
Migraines, Cardiovascular Risk, & VasoconstrictorsPublished: November 17th 2017 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
Complementary Studies Point to How to Boost CRC Screening Rates
2
FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy
3
A Look at Lynkuet® (Elinzanetant) for the Treatment of Moderate to Severe Vasomotor Symptoms
4
Impact of Vasomotor Symptoms on Patient Quality of Life
5
